These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 14693525

  • 1. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
    Demicheli C, Ochoa R, da Silva JB, Falcão CA, Rossi-Bergmann B, de Melo AL, Sinisterra RD, Frézard F.
    Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
    [Abstract] [Full Text] [Related]

  • 2. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA, Marco JD, Calvopina M, Kato H, Korenaga M, Hashiguchi Y.
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [Abstract] [Full Text] [Related]

  • 3. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.
    Fournet A, Ferreira ME, Rojas De Arias A, Torres De Ortiz S, Fuentes S, Nakayama H, Schinini A, Hocquemiller R.
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2447-51. PubMed ID: 8913444
    [Abstract] [Full Text] [Related]

  • 4. Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
    Lanza JS, Fernandes FR, Corrêa-Júnior JD, Vilela JM, Magalhães-Paniago R, Ferreira LA, Andrade MS, Demicheli C, Melo MN, Frézard F.
    Int J Nanomedicine; 2016 Nov; 11():2305-18. PubMed ID: 27307731
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T, Lehn N, Landthaler M, Stolz W.
    Dermatology; 2003 Nov; 206(3):269-72. PubMed ID: 12673089
    [Abstract] [Full Text] [Related]

  • 6. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
    Costa Filho AV, Lucas IC, Sampaio RN.
    Rev Soc Bras Med Trop; 2008 Nov; 41(4):424-7. PubMed ID: 18853022
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E.
    Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
    [Abstract] [Full Text] [Related]

  • 8. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
    Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y.
    Arch Dermatol; 2006 Dec; 142(12):1575-9. PubMed ID: 17178983
    [Abstract] [Full Text] [Related]

  • 9. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S, Marr JJ.
    N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379
    [Abstract] [Full Text] [Related]

  • 10. Enhanced oral delivery of antimony from meglumine antimoniate/beta-cyclodextrin nanoassemblies.
    Frézard F, Martins PS, Bahia AP, Le Moyec L, de Melo AL, Pimenta AM, Salerno M, da Silva JB, Demicheli C.
    Int J Pharm; 2008 Jan 22; 347(1-2):102-8. PubMed ID: 17656054
    [Abstract] [Full Text] [Related]

  • 11. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
    Shamsi Meymandi S, Javadi A, Dabiri S, Shamsi Meymandi M, Nadji M.
    Arch Iran Med; 2011 Jul 22; 14(4):238-43. PubMed ID: 21726098
    [Abstract] [Full Text] [Related]

  • 12. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec 22; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 13. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR, de Jesus LCL, Soares RP, Silva LDM, Pinto BAS, Melo MN, Paes AMA, Pereira SRF.
    Antimicrob Agents Chemother; 2017 Jun 22; 61(6):. PubMed ID: 28320726
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta).
    Grimaldi G, Porrozzi R, Friedrich K, Teva A, Marchevsky RS, Vieira F, Miekeley N, Paumgartten FJ.
    Antimicrob Agents Chemother; 2010 Jan 22; 54(1):502-5. PubMed ID: 19822700
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
    Solomon M, Ollech A, Pavlotsky F, Barzilai A, Schwartz E, Baum S, Astman N.
    Acta Derm Venereol; 2024 Apr 29; 104():adv35089. PubMed ID: 38682801
    [Abstract] [Full Text] [Related]

  • 16. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
    Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Pérez M, Nicholls RS, Gore Saravia N.
    J Infect Dis; 2012 Feb 15; 205(4):684-92. PubMed ID: 22238470
    [Abstract] [Full Text] [Related]

  • 17. Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.
    Vargas-Gonzalez A, Canto-Lara SB, Damian-Centeno AG, Andrade-Narvaez FJ.
    Am J Trop Med Hyg; 1999 Dec 15; 61(6):960-3. PubMed ID: 10674678
    [Abstract] [Full Text] [Related]

  • 18. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec 15; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 19. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA, Falcão CA, de Oliveira FB, Marbeuf C, Garnier-Suillerot A, Demicheli C, Rossi-Bergmann B, Frézard F.
    Chem Biol Interact; 2006 Apr 15; 160(3):217-24. PubMed ID: 16524568
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis.
    Peixoto JF, Gonçalves-Oliveira LF, Souza-Silva F, de Castro Côrtes LM, Finkelstein LC, Dias-Lopes G, Patricio BFC, Lima CGS, Rocha HVA, da Silva FC, Ferreira VF, Pereira BAS, Alves CR.
    Int J Parasitol Drugs Drug Resist; 2024 Apr 15; 24():100525. PubMed ID: 38359731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.